
|Videos|September 23, 2020
Management of Adverse Effects in R/R HER2+ mBC
Advertisement
Counseling patients and the management of adverse effects of newer regimens in relapsed/refractory HER2+ metastatic breast cancer as well as advice for oncology nurses.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































